In this guest editorial, Dr. Kent Grindstaff from BIoIVT discusses how the FDA’s draft guidance on New Approach Methodologies (NAMs) signifies a structured advancement in integrating innovative, non-animal methods into preclinical drug development
In this guest editorial, Dr. Courtney Noah, BioIVT's Vice President of Scientific Affairs, explores why disease state donors and purified immune subsets improve predictive safety models
In this guest editorial, Daryl Waggott, Head of Data Products, BioIVT, highlights the critical role of ethically sourced, clinically linked biospecimen datasets in advancing computational tumor biology.
Guest editorial by Courtney Noah, Ph.D., and Daryl Waggott, MSc
